Amarin | AMRN - Stammkapital

Aktienkurs
15.23
Täglich Wechseln
-0.11 -0.70%
Monatlich
-2.60%
Jährlich
83.53%
Q1 Prognose
14.88




Stammkapital Veränderung Datum
AbbVie USD 1.77B 1.75B 2025-06
Alnylam Pharmaceuticals USD 132.38M 585K 2025-12
Amarin USD 20.8M 28K 2025-09
AstraZeneca USD 1.55B 206K 2025-12
BioCryst Pharmaceuticals USD 213.06M 2.54M 2025-12
DBV Technologies USD 11.65M 1000 2025-03
Esperion Therapeutics USD 245.22M 39.79M 2025-12
GlaxoSmithKline GBP 4.08B 49.43M 2025-12
Halozyme Therapeutics USD 117.78M 259K 2025-12
Heron Therapeutics USD 1.52M 14K 2024-09
Ionis Pharmaceuticals USD 161.97M 836K 2025-12
Nektar Therapeutics USD 19K 0 2024-09
Neurocrine Biosciences USD 100.1M 400K 2025-12
Novartis USD 1.94B 23.4M 2025-06